Abstract library

14 results for "CD105".
#167 Localization of Sporadic Neuroendocrine Tumors by Gene expression Analysis of Their Metastases
Introduction: Primary neuroendocrine tumors (NETs) are rare and often difficult to detect, leading to diagnosis late in their development. Cases in which the primary cannot be located are denoted as CUP-Syndrome.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dipl. Biol. Nicole Posorski
#390 An Increasing Incidence of GEP-NETs in Chengdu City with a Population of 14 Million in China
Introduction: The annual incidence of GEP-NETs in China is still unclear. All histopathology and cytopathology reports have yet to be collected in a national archive. No national or regional survey on GEP-NETs has been approved. West China Hospital (WCH), a university hospital located in Chengdu City with a population of 14 million, has established a series of databases in recent years.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Tang Chengwei
Authors: Guo L, Wang C, Liu W, Zhong M, ...
#418 Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) are heterogeneous neoplasms with different malignancy. Plasma chromogranin A (CgA) may play an important role in predicting outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sara Massironi
Keywords: CgA, GEP-NET
#821 Incidence of Secondary Neoplasia in Patients with Neuroendocrine Tumor: An Analysis of the SwissNET Database
Introduction: NET are believed to be associated with an increased risk for secondary neoplasia. Previous studies suggest incidence rates between 7% and 46%.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: nnika Blank
Authors: Blank A, Iff S, Stettler C, ...
#891 Metastatic G1-G2 Neuroendocrine Tumors (WDNET) Treated with Sequences of Different Somatostatine Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): A Single Center Experience
Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Riccardo Marconcini
#1001 Forkheadbox Proteins as Novel Drug Targets in Gastroenteropancreatic Neuroendocrine Tumor Disease: Inhibition of FoxM1 Exerts Antiproliferative Effects in GEP-NEN Cell Lines
Introduction: Forkheadbox proteins (Fox proteins) are transcriptions factors. They are highly conserved key players in a large number of cellular processes. Fox proteins have been described as acting as both tumor suppressors and oncogenes. Most notably, they operate in the context of the majority of cancer-related pathways. Information about the fuunction of these proteins in gastroenteropancreatic neuroendocrine neoplasias is scant.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Patricia Grabowski
#1312 Epigenetic Remodeling upon DAXX and ATRX Loss in Pancreatic Neuro-endocrine tumors (pNETs)
Introduction: DAXX and or ATRX loss occur in 40% of sporadic pNETs. DAXX and ATRX participate in the cell epigenetic status maintenance. Epigenetic changes influence gene expression, function of telomeres and genomic stability. We hypothesize that DAXX/ATRX loss drives tumor progression in pNET through epigenetic changes affecting genomic stability.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Ilaria Marinoni
Keywords: DAXX/ATRX, epigenetic, CIN
#1482 Duodenum Preserving Pancreatic Head Resection for Neuroendocrine Pancreatic Tumors of the Head of the Pancreas.
Introduction: Duodenum Preserving Pancreatic Head Resection (DPPHR) is a surgical procedure uncommonly used in benign tumors of the head of the pancreas as alternative to pancreaticoduodenectomy.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Doctor Valbona Liço
Keywords: dpphr
#1668 Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3
Introduction: The classification of lung neuroendocrine neoplasms (Lung-NENs) according to the WHO classification 2010 for GEP-NENs, including a provisional category for Lung-NET G3 with Ki67 >20%, may have prognostic implications.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Authors: Kasajima A, Oka N, Ishida H, Sakurada A, ...
Keywords: Lung NEN
#2236 Carcinoid Syndrome Open Questions – Evaluations from a Real Life Setting
Introduction: Carcinoid syndrome (CS) is frequent in patients with neuroendocrine neoplasia of the small bowel and limits quality of life and may influence prognosis compared to patients with non-functional neuroendocrine neoplasia.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Robert Fijalkowski
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team